In addition to these molecules, research and clinical trials have been conducted to investigate whether targeting other types of inhibitory receptors, including lymphocyte activation gene 3 (LAG3), T cell membrane protein 3 (TIM3), and T cell immunoglobulin and ITIM domains (TIGIT), might enhance the efficacy of cancer immunotherapy (59–62). This evidence concerns the gene HAVCR2 and cancer.